The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

"PEPFAR funding protection offers “hope” for people living with HIV" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The International AIDS Society (IAS) on Sunday called on President Trump to increase funding for AIDS research, warning that his proposed spending cuts could cause deaths. IAS president Linda-Gail ...